Summary

The vascular access device market is projected to reach USD 8.68 billion by 2031 from USD 6.27 billion in 2026, at a CAGR of 6.7% from 2026 to 2031.

The vascular access device market is expanding due to the rise in chronic diseases such as cancer, heart disorders, and kidney failure, all of which require intravenous therapies. The increase in hospitalizations, surgical procedures, and the demand for critical care and emergency services is driving the need for these devices. Additionally, advancements in technology—such as safety-engineered devices, antimicrobial coatings, and ultrasound-guided placement—are enhancing clinical outcomes, reducing complications, and supporting broader adoption of vascular access devices. Besides, the growing elderly population, rising ambulatory care and home healthcare facilities, and the tremendous emphasis on infection control and patient safety are all driving the demand for vascular access devices in the healthcare system.

“Based on type, the peripheral vascular access device segment is expected to experience the highest CAGR during the forecast period.”
By type, the peripheral vascular access device segment is estimated to lead the vascular access device market because of the increasing need for short-term intravenous therapy in hospitals and other medical facilities. The demand for peripheral vascular access devices has been further propelled by the rise in chronic diseases, surgical and emergency procedures, and increased use of IV medications and fluids. Apart from these benefits, the devices are also preferred for their insertion convenience, cost, and lower risk of severe complications than central access. Moreover, new catheter materials, engineered safety designs that avoid needlestick injury, and a movement toward outpatient and more affordable care models are also contributing to the market's growth.

“Based on application, the drug administration segment is projected to register the highest CAGR during the forecast period.”
By application, the drug administration segment is projected to grow at the highest rate due to the increasing use of intravenous therapies in the treatment of chronic illnesses like cancer, heart diseases, infections, and autoimmune disorders. Demand is additionally supported by increasing dependence on IV drug delivery for chemotherapy, antibiotics, biologics, and pain management, owing to its rapid onset and higher bioavailability. Besides, the increase in hospital admissions, the extension of outpatient infusion centers, and home-based IV therapy are all contributing to the segment’s growth. The innovative features of vascular access devices, such as better dosing accuracy, lower infection risks, and long-term drug delivery support, are all contributing to their adoption in healthcare settings.

“Based on end user, the clinic & ambulatory care centers segment is expected to grow at the highest rate during the forecast period.”
The rise of clinics and ambulatory care centers has been a major factor in the growth of the vascular access device market, mainly driven by the trend of hospitals moving patients to outpatient care, which, in turn, is expected to cut down on overall healthcare costs. Besides, the scale-up of minimally invasive procedures, infusion therapies, chronic disease management, and same-day surgeries has contributed to the need for efficient and safe vascular access in these environments. Access to easy-to-use, low-complication vascular access devices is a major factor behind the rapid adoption by clinics and ASCs. Also, favorable reimbursement systems, patient preference for shorter recovery times, and the growth of stand-alone specialty clinics are some of the reasons further contributing to the market expansion.

“Asia Pacific is estimated to register the highest CAGR during the forecast period.”
The growth of outpatient services and facilities has significantly boosted the vascular access device market. Hospitals and patients are increasingly shifting their preference from inpatient to outpatient services due to the cost savings and reduced inconvenience associated with outpatient care. The rising use of vascular access devices for small surgeries, infusion therapies, chemotherapy administration, and chronic disease management has also contributed to market growth. Additionally, advancements in technology have enabled the quick, sterile, and straightforward insertion of these devices, further enhancing their appeal. Other favorable factors for the use of vascular access devices in clinics and ambulatory care centers include supportive reimbursement policies, quick procedure turnaround times, and patients' growing preference for same-day treatments.

Key players in the vascular access device market
Some of the major players in this market are Becton, Dickinson and Company (US), Teleflex Incorporated (US), ICU Medical, Inc. (US), B. Braun SE (Germany), AngioDynamics, Inc. (US), Medtronic, Plc (Ireland), Merit Medical Systems Inc. (US), Terumo Corporation (Japan), Nipro (Japan), Vygon (France), AMECATH (Egypt), Medical Components, Inc. (US), HealthLine Medical Products (US), Cook Medical (US), and Access Vascular, Inc. (US).

Research Coverage:
The report analyzes the vascular access device market and aims to estimate its size and future growth potential based on various segments, such as angioplasty stents, endovascular aneurysm repair stent grafts, inferior cava filters, catheters, angioplasty balloons, plaque modification devices, hemodynamic flow alteration devices, other devices, and end users. The report includes a product portfolio matrix of various vascular access devices available in the market. It also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.
Reasons to Buy the Report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall vascular access device market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report provides insights into the following pointers:
・Analysis of key divers (Growing prevalence of lifestyle diseases, increasing number of chemotherapy procedures, growing use of vascular access devices in pediatric patients), restraints (High cost associated with placement and maintenance of vascular access device, product recalls and failures), challenges (Shortage of skilled professionals, risks associated with vascular access devices), and opportunities (Technological Advancements, growth in number of hospitals)
・Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the vascular access device market.
・Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new product launches in the vascular access device market
・Market Development: Comprehensive information on the lucrative emerging markets by angioplasty stents, structural heart devices, catheters, angioplasty balloons, plaque modification devices, hemodynamic flow alteration devices, other devices, and end users.
・Market Diversification: Exhaustive information about new products and services or product and service enhancements, growing geographies, recent developments, and investments in the vascular access device market.
・Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of products and services, and capacities of the major competitors in the vascular access device market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 38
1.1 STUDY OBJECTIVES 38
1.2 MARKET DEFINITION 38
1.3 STUDY SCOPE 39
1.3.1 MARKETS COVERED & REGIONAL SEGMENTATION 39
1.3.2 INCLUSIONS & EXCLUSIONS 40
1.3.3 YEARS CONSIDERED 41
1.3.4 CURRENCY CONSIDERED 41
1.4 STAKEHOLDERS 42
1.5 SUMMARY OF CHANGES 42
2 EXECUTIVE SUMMARY 43
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 43
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 44
2.3 DISRUPTIVE TRENDS IN VASCULAR ACCESS DEVICE MARKET 45
2.4 HIGH GROWTH SEGMENTS 46
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 47
3 PREMIUM INSIGHTS 48
3.1 VASCULAR ACCESS DEVICE MARKET OVERVIEW 48
3.2 ASIA PACIFIC: VASCULAR ACCESS DEVICE MARKET, BY COUNTRY AND END USER 49
3.3 GEOGRAPHIC SNAPSHOT OF VASCULAR ACCESS DEVICE MARKET 50
4 MARKET OVERVIEW 51
4.1 INTRODUCTION 51
4.2 MARKET DYNAMICS 51
4.2.1 DRIVERS 52
4.2.1.1 Rising global prevalence of chronic and lifestyle-related diseases 52
4.2.1.2 Rapid growth in the geriatric population and associated vascular disease burden 53
4.2.1.3 Favorable reimbursement scenario for vascular procedures 54
4.2.1.4 Increase in cancer incidence driving demand for vascular access devices in chemotherapy 55
4.2.2 RESTRAINTS 56
4.2.2.1 High costs of vascular access device placement and maintenance 56
4.2.2.2 Rising product failures and device recalls 56
4.2.3 OPPORTUNITIES 57
4.2.3.1 Technological innovation in vascular access devices 57
4.2.3.2 Growing adoption of midline catheters in clinical and outpatient settings 58
4.2.4 CHALLENGES 58
4.2.4.1 Clinical complications associated with vascular access devices 58
4.2.4.2 Shortage of skilled professionals for vascular access device placement and management 59
4.3 UNMET NEEDS AND WHITE SPACES 59
4.3.1 UNMET NEEDS IN VASCULAR ACCESS DEVICE MARKET 59
4.3.2 WHITE SPACE OPPORTUNITIES 60
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 62
4.4.1 INTERCONNECTED MARKETS 62
4.4.2 CROSS-SECTOR OPPORTUNITIES 63
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 64
5 INDUSTRY TRENDS 65
5.1 PORTER’S FIVE FORCES ANALYSIS 65
5.1.1 THREAT OF NEW ENTRANTS 66
5.1.2 THREAT OF SUBSTITUTES 67
5.1.3 BARGAINING POWER OF BUYERS 67
5.1.4 BARGAINING POWER OF SUPPLIERS 67
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 67
5.2 MACROECONOMIC OUTLOOK 68
5.2.1 INTRODUCTION 68
5.2.2 GDP TRENDS & FORECAST 68
5.2.3 TRENDS IN GLOBAL MEDICAL DEVICES INDUSTRY 69
5.2.4 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 70
5.3 SUPPLY CHAIN ANALYSIS 70
5.4 VALUE CHAIN ANALYSIS 72
5.5 ECOSYSTEM ANALYSIS 74
5.6 PRICING ANALYSIS 75
5.6.1 AVERAGE SELLING PRICE TREND OF CENTRAL VENOUS ACCESS DEVICES,
BY TYPE (2023–2025) 75
5.6.2 AVERAGE SELLING PRICE TREND OF PERIPHERAL VASCULAR ACCESS DEVICES, BY TYPE (2023–2025) 76
5.6.3 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY APPLICATION (2023–2025) 77
5.6.4 AVERAGE SELLING PRICE TREND, BY REGION (2023–2025) 77
5.7 TRADE ANALYSIS 78
5.7.1 IMPORT DATA FOR HS CODE 9018.39 79
5.7.2 EXPORT DATA FOR HS CODE 9018.39 79
5.8 KEY CONFERENCES & EVENTS, 2026–2027 80
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 81
5.10 INVESTMENT & FUNDING SCENARIO 82
5.11 CASE STUDY ANALYSIS 83
 
5.12 IMPACT OF US TARIFFS–VASCULAR ACCESS DEVICE MARKET 85
5.12.1 INTRODUCTION 85
5.12.2 KEY TARIFF RATES 85
5.12.3 PRICE IMPACT ANALYSIS 86
5.12.4 IMPACT ON COUNTRIES/REGIONS 87
5.12.5 IMPACT ON END-USE INDUSTRIES 89
5.12.5.1 Hospitals 89
5.12.5.2 Clinics 89
5.12.5.3 Ambulatory care centers 89
5.12.5.4 Other end users 90
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 91
6.1 KEY EMERGING TECHNOLOGIES 91
6.1.1 NEEDLE-FREE AND CLOSED IV SYSTEMS 91
6.1.2 ULTRASOUND-GUIDED AND TIP-NAVIGATION SYSTEMS 91
6.2 COMPLEMENTARY TECHNOLOGIES 92
6.2.1 VEIN VISUALIZATION SYSTEMS 92
6.2.2 INFUSION PUMPS AND FLOW CONTROL SYSTEMS 92
6.3 ADJACENT TECHNOLOGIES 92
6.3.1 ULTRASOUND SYSTEMS FOR VASCULAR ACCESS 92
6.4 TECHNOLOGY/PRODUCT ROADMAP 93
6.4.1 NEAR TERM (2025–2027) 93
6.4.2 MID TERM (2028–2030) 94
6.4.3 LONG TERM (2030+) 94
6.5 PATENT ANALYSIS 96
6.5.1 JURISDICTION & TOP APPLICANT ANALYSIS 97
6.6 FUTURE APPLICATIONS 99
6.6.1 HOME-BASED AND REMOTE INFUSION THERAPIES 99
6.6.2 SMART VASCULAR ACCESS DEVICES WITH SENSOR INTEGRATION 99
6.6.3 EXPANSION OF CRITICAL CARE AND EXTRACORPOREAL THERAPIES 100
6.6.4 ULTRASOUND-GUIDED AND ROBOTIC VASCULAR ACCESS PLACEMENT 100
6.6.5 ADVANCED ANTIMICROBIAL AND BIOCOMPATIBLE CATHETER TECHNOLOGIES 100
6.6.6 PRECISION MEDICINE AND SPECIALIZED DRUG DELIVERY APPLICATIONS 100
6.7 IMPACT OF AI/GENERATIVE AI ON VASCULAR ACCESS DEVICE MARKET 101
6.7.1 BEST PRACTICES IN VASCULAR ACCESS DEVICE MARKET 102
6.7.2 CASE STUDIES OF AI IMPLEMENTATION IN VASCULAR ACCESS DEVICE MARKET 103
6.7.3 INTERCONNECTED ADJACENT ECOSYSTEMS AND IMPACT ON MARKET PLAYERS 104
6.7.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN VASCULAR ACCESS DEVICE MARKET 105
7 REGULATORY LANDSCAPE & SUSTAINABILITY INITIATIVES 106
7.1 REGIONAL REGULATIONS & COMPLIANCE 106
7.1.1 REGULATORY ANALYSIS 106
7.1.1.1 North America 106
7.1.1.1.1 US 106
7.1.1.1.2 Canada 106
7.1.1.2 Europe 107
7.1.1.3 Asia Pacific 107
7.1.1.4 Latin America 108
7.1.1.5 Middle East & Africa 108
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 109
7.2 INDUSTRY STANDARDS 111
7.2.1 QUALITY MANAGEMENT SYSTEM FOR MEDICAL DEVICES (ISO 13485) 111
7.2.2 BIOLOGICAL EVALUATION OF MEDICAL DEVICES (ISO 10993) 111
7.2.3 INTRAVASCULAR CATHETERS (ISO 10555) 111
7.2.4 RISK MANAGEMENT FOR MEDICAL DEVICES (ISO 14971) 112
7.3 SUSTAINABILITY INITIATIVES 112
7.3.1 ENVIRONMENTAL SUSTAINABILITY IN VASCULAR ACCESS PRODUCT LIFECYCLE- BECTON, DICKINSON AND COMPANY 112
7.3.2 RESOURCE EFFICIENCY AND WASTE REDUCTION IN MEDICAL DEVICE MANUFACTURING – VYGON 112
7.3.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 113
7.3.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 114
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 116
8.1 DECISION-MAKING PROCESS 116
8.2 KEY BUYER STAKEHOLDERS AND THEIR EVALUATION CRITERIA 118
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 118
8.2.2 BUYING CRITERIA 119
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 121
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 122
8.5 MARKET PROFITABILITY 122
9 VASCULAR ACCESS DEVICE MARKET, BY TYPE 124
9.1 INTRODUCTION 125
9.2 CENTRAL VENOUS ACCESS DEVICES 125
9.2.1 PERIPHERALLY INSERTED CENTRAL CATHETERS 127
9.2.1.1 Enhanced convenience and risk reduction boost PICC adoption 127
9.2.2 TUNNELED CATHETERS 128
9.2.2.1 Advantages of tunneled catheters, such as lower risk of infection and lower chances of accidental removal, to boost demand 128
9.2.2.2 Volume analysis for tunneled cathers market, by region,
2024–2031 (Units) 130
9.2.3 NON-TUNNELED CATHETERS 130
9.2.3.1 Increasing adoption of non-tunneled CVCs driven by affordability and their critical role in emergency care 130
9.2.3.2 Volume analysis for non-tunneled cathers market, by region,
2024–2031 (Units) 132
9.2.4 IMPLANTABLE PORTS 132
9.2.4.1 Implantable conventional ports 134
9.2.4.1.1 Lowest risk of infection associated with implanted ports to support growth 134
9.2.4.2 Implantable power injectable ports 135
9.2.4.2.1 Increasing chemotherapy treatments and high-flow infusion needs fuel demand for implantable power injectable ports 135
9.3 PERIPHERAL VASCULAR ACCESS DEVICES 136
9.3.1 PERIPHERAL VENOUS ACCESS DEVICES 138
9.3.1.1 Peripheral intravenous catheters 140
9.3.1.1.1 Growing hospitalizations and widespread IV therapy drive demand for peripheral intravenous catheters in healthcare 140
9.3.1.2 Volume analysis for peripheral intravenous catheters market,
by region, 2024–2031 (Units) 141
9.3.1.3 Midline catheters 141
9.3.1.3.1 Cost-efficiency and extended treatment capabilities drive midline catheter growth in vascular access markets 141
9.3.1.3.2 MST max barrier midline catheters 143
9.3.1.3.3 Integrated/Accelerated midline catheters 144
9.3.1.4 Butterfly/Winged steel needles 146
9.3.1.4.1 Wide usage of winged steel needles in blood sampling and diagnosis to propel growth 146
9.3.2 PERIPHERAL ARTERIAL ACCESS DEVICES 148
9.3.2.1 Real-time hemodynamic monitoring in critical and surgical care to drive market 148
9.3.2.2 Volume analysis for peripheral arterial access devices market,
by region, 2024–2031 (Units) 150
9.4 ACCESSORIES 150
9.4.1 RECURRENT NEED FOR ACCESSORIES TO BOOST MARKET 150
9.5 INTRAOSSEOUS VASCULAR ACCESS DEVICES 152
9.5.1 INCREASING INCIDENCE OF CARDIAC ARRESTS TO DRIVE DEMAND FOR INTRAOSSEOUS VASCULAR ACCESS DEVICES 152
10 VASCULAR ACCESS DEVICE MARKET, BY ROUTE OF INSERTION 154
10.1 INTRODUCTION 155
10.2 INTRAVENOUS 155
10.2.1 GROWING HOSPITALIZATIONS AND DEMAND FOR FAST THERAPEUTIC EFFECTS DRIVE USAGE OF INTRAVENOUS ROUTE 155
 
10.3 SUBCUTANEOUS 157
10.3.1 RISING CANCER CASES AND DEMAND FOR LONG-TERM THERAPIES DRIVE SEGMENTAL GROWTH 157
10.4 INTRAOSSEOUS 158
10.4.1 RISING PREVALENCE OF CORONARY ARTERY DISEASES TO DRIVE MARKET GROWTH 158
11 VASCULAR ACCESS DEVICE MARKET, BY APPLICATION 160
11.1 INTRODUCTION 161
11.2 DRUG ADMINISTRATION 161
11.2.1 CHEMOTHERAPY 163
11.2.1.1 Rising cancer cases to propel chemotherapy demand and boost market growth 163
11.2.2 OTHER DRUG ADMINISTRATION APPLICATIONS 164
11.3 FLUID & NUTRITION ADMINISTRATION 165
11.3.1 GROWING USE OF PERIPHERAL VASCULAR ACCESS DEVICES FOR SHORT-TERM NUTRITIONAL THERAPY TO SUPPORT MARKET 165
11.4 BLOOD TRANSFUSION 167
11.4.1 FREQUENT NEED FOR BLOOD TRANSFUSION IN THE TREATMENT OF VARIOUS CONDITIONS TO BOOST GROWTH 167
11.5 DIAGNOSTICS & TESTING 168
11.5.1 GROWING POPULARITY OF PERIPHERAL LINES FOR DIAGNOSTIC & TESTING APPLICATIONS TO DRIVE MARKET GROWTH 168
12 VASCULAR ACCESS DEVICE MARKET, BY END USER 170
12.1 INTRODUCTION 171
12.2 HOSPITALS 171
12.2.1 PUBLIC HOSPITALS 173
12.2.1.1 Affordability and accessibility drive patients toward public hospitals 173
12.2.2 PRIVATE HOSPITALS 174
12.2.2.1 Rising availability of specialized treatments and diagnostic services in private hospitals fuels growth 174
12.3 CLINICS 175
12.3.1 INCREASING DEMAND FOR OUTPATIENT PROCEDURES AND COST-EFFECTIVE TREATMENTS TO PROPEL MARKET 175
12.4 AMBULATORY CARE CENTERS 177
12.4.1 INCREASING DEMAND FOR OUTPATIENT PROCEDURES AND COST-EFFECTIVE TREATMENTS TO SUPPORT MARKET GROWTH 177
12.5 OTHER END USERS 178
 
13 VASCULAR ACCESS DEVICE MARKET, BY REGION 180
13.1 INTRODUCTION 181
13.2 NORTH AMERICA 181
13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 181
13.2.2 NORTH AMERICA VOLUME ANALYSIS FOR CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE (UNITS) 184
13.2.3 NORTH AMERICA VOLUME ANALYSIS FOR PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE (UNITS) 185
13.2.4 US 188
13.2.4.1 US to dominate North American vascular access device market during forecast period 188
13.2.5 CANADA 192
13.2.5.1 Rising cancer prevalence and advanced research initiatives propel Canada's vascular access device market growth. 192
13.3 EUROPE 197
13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 197
13.3.2 EUROPE VOLUME ANALYSIS FOR CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE (UNITS) 199
13.3.3 EUROPE VOLUME ANALYSIS FOR PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE (UNITS) 200
13.3.4 GERMANY 203
13.3.4.1 Germany to dominate European vascular access device market during forecast period 203
13.3.5 UK 207
13.3.5.1 Increased need for intravenous treatments due to CKD and CHD drives market growth 207
13.3.6 FRANCE 212
13.3.6.1 Growing elderly population and healthcare needs foster rapid market growth for vascular access devices in France 212
13.3.7 ITALY 216
13.3.7.1 Strong healthcare policies by government to propel growth 216
13.3.8 SPAIN 221
13.3.8.1 Growing geriatric population to increase demand for vascular access devices 221
13.3.9 REST OF EUROPE 225
13.4 ASIA PACIFIC 229
13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 229
13.4.2 ASIA PACIFIC: VOLUME ANALYSIS FOR CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE (UNITS) 232
13.4.3 ASIA PACIFIC: VOLUME ANALYSIS FOR PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE (UNITS) 233
13.4.4 CHINA 236
13.4.4.1 China to dominate Asia Pacific’s vascular access device market during forecast period. 236
 
13.4.5 INDIA 241
13.4.5.1 Increasing healthcare expenditure and chronic disease prevalence support market growth in India 241
13.4.6 JAPAN 245
13.4.6.1 Growing healthcare needs among elderly individuals fuel vascular access device market expansion in Japan. 245
13.4.7 AUSTRALIA 250
13.4.7.1 Rising demand for pharmaceuticals and increasing advancements in drug formulations to drive market 250
13.4.8 SOUTH KOREA 254
13.4.8.1 Increasing diabetes and CKD prevalence to drive the market growth 254
13.4.9 REST OF ASIA PACIFIC 259
13.5 LATIN AMERICA 263
13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 263
13.5.2 LATIN AMERICA: VOLUME ANALYSIS FOR CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE (UNITS) 265
13.5.3 LATIN AMERICA: VOLUME ANALYSIS FOR PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE (UNITS) 266
13.5.4 BRAZIL 269
13.5.4.1 Expanding chronic disease prevalence in Brazil supports demand growth 269
13.5.5 MEXICO 274
13.5.5.1 Growing ESRD cases and obesity trends to propel market growth 274
13.5.6 REST OF LATIN AMERICA 278
13.6 MIDDLE EAST & AFRICA 283
13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 283
13.6.2 MIDDLE EAST & AFRICA: VOLUME ANALYSIS FOR CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE (UNITS) 285
13.6.3 MIDDLE EAST & AFRICA: VOLUME ANALYSIS FOR CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE (UNITS) 286
13.6.4 GCC COUNTRIES 289
13.6.4.1 Kingdom of Saudi Arabia 293
13.6.4.1.1 Rising chronic disease burden and strategic healthcare investments to drive market 293
13.6.4.2 United Arab Emirates 298
13.6.4.2.1 Healthcare infrastructural development and rising medical tourism to drive demand 298
13.6.4.3 Rest of GCC Countries 302
13.6.5 REST OF MIDDLE EAST & AFRICA 306
 
14 COMPETITIVE LANDSCAPE 311
14.1 INTRODUCTION 311
14.2 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN, 2024–2026 311
14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VASCULAR ACCESS DEVICE MARKET 312
14.3 REVENUE ANALYSIS, 2023–2025 314
14.4 MARKET SHARE ANALYSIS, 2025 315
14.4.1 GLOBAL MARKET SHARE ANALYSIS (2025) 315
14.4.2 US MARKET SHARE ANALYSIS (2025) 317
14.4.3 EUROPE MARKET SHARE ANALYSIS (2025) 318
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 319
14.5.1 STARS 319
14.5.2 EMERGING LEADERS 319
14.5.3 PERVASIVE PLAYERS 319
14.5.4 PARTICIPANTS 319
14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 321
14.5.5.1 Company footprint 321
14.5.5.2 Type footprint 322
14.5.5.3 Route of insertion footprint 322
14.5.5.4 Application footprint 323
14.5.5.5 Region footprint 324
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 325
14.6.1 PROGRESSIVE COMPANIES 325
14.6.2 RESPONSIVE COMPANIES 325
14.6.3 DYNAMIC COMPANIES 325
14.6.4 STARTING BLOCKS 325
14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 327
14.6.5.1 Detailed list of key startups/SMEs 327
14.6.5.2 Competitive benchmarking of key startups/SMEs 328
14.7 COMPANY VALUATION AND FINANCIAL METRICS 329
14.7.1 FINANCIAL METRICS 329
14.7.2 COMPANY VALUATION 329
14.8 BRAND/PRODUCT COMPARISON 330
14.9 COMPETITIVE SCENARIO 331
14.9.1 PRODUCT LAUNCHES & APPROVALS 331
14.9.2 DEALS 332
14.9.3 EXPANSIONS 333
14.9.4 OTHER DEVELOPMENTS 335
 
15 COMPANY PROFILES 336
15.1 KEY PLAYERS 336
15.1.1 BECTON, DICKINSON AND COMPANY 336
15.1.1.1 Business overview 336
15.1.1.2 Products offered 337
15.1.1.3 Recent developments 343
15.1.1.3.1 Product launches & approvals 343
15.1.1.3.2 Other developments 343
15.1.1.4 MnM view 344
15.1.1.4.1 Right to win 344
15.1.1.4.2 Strategic choices 344
15.1.1.4.3 Weaknesses & competitive threats 344
15.1.2 TERUMO CORPORATION 345
15.1.2.1 Business overview 345
15.1.2.2 Products offered 346
15.1.2.3 Recent developments 347
15.1.2.3.1 Product launches & approvals 347
15.1.2.3.2 Expansions 348
15.1.2.3.3 Other developments 348
15.1.3 TELEFLEX INCORPORATED 349
15.1.3.1 Business overview 349
15.1.3.2 Products offered 350
15.1.3.3 Recent developments 352
15.1.3.3.1 Product launches & approvals 352
15.1.3.3.2 Deals 353
15.1.3.3.3 Other developments 353
15.1.3.4 MnM view 354
15.1.3.4.1 Right to win 354
15.1.3.4.2 Strategic choices 354
15.1.3.4.3 Weaknesses & competitive threats 354
15.1.4 ICU MEDICAL INC. 355
15.1.4.1 Business overview 355
15.1.4.2 Products offered 356
15.1.4.3 Recent developments 359
15.1.4.3.1 Product launches & approvals 359
15.1.4.3.2 Expansions 360
15.1.4.3.3 Other developments 360
15.1.4.4 MnM view 360
15.1.4.4.1 Right to win 360
15.1.4.4.2 Strategic choices 361
15.1.4.4.3 Weaknesses & competitive threats 361
 
15.1.5 B. BRAUN SE 362
15.1.5.1 Business overview 362
15.1.5.2 Products offered 363
15.1.5.3 Recent developments 368
15.1.5.3.1 Product launches & approvals 368
15.1.5.3.2 Other developments 369
15.1.5.4 MnM view 369
15.1.5.4.1 Right to win 369
15.1.5.4.2 Strategic choices 369
15.1.5.4.3 Weaknesses and competitive threats 369
15.1.6 MERIT MEDICAL SYSTEMS 370
15.1.6.1 Business overview 370
15.1.6.2 Products offered 371
15.1.6.3 Recent developments 373
15.1.6.3.1 Product launches 373
15.1.6.3.2 Deals 374
15.1.6.3.3 Other developments 374
15.1.7 NIPRO CORPORATION 375
15.1.7.1 Business overview 375
15.1.7.2 Products offered 376
15.1.7.3 Recent developments 377
15.1.7.3.1 Deals 377
15.1.7.3.2 Expansions 377
15.1.7.3.3 Other developments 378
15.1.7.4 MnM view 378
15.1.7.4.1 Right to Win 378
15.1.7.4.2 Strategic choices 378
15.1.7.4.3 Weaknesses & competitive threats 379
15.1.8 VYGON 380
15.1.8.1 Business overview 380
15.1.8.2 Products offered 380
15.1.8.3 Recent developments 386
15.1.8.3.1 Deals 386
15.1.9 ANGIODYNAMICS 387
15.1.9.1 Business overview 387
15.1.9.2 Products offered 388
15.1.9.3 Recent developments 389
15.1.9.3.1 Product launches and approvals 389
 
15.1.10 MOZARC MEDICAL HOLDING LLC 390
15.1.10.1 Business overview 390
15.1.10.2 Products offered 390
15.1.10.3 Recent developments 391
15.1.10.3.1 Deals 391
15.1.10.3.2 Other developments 392
15.1.11 SPECTRUM VASCULAR 393
15.1.11.1 Business overview 393
15.1.11.2 Products offered 393
15.1.11.3 Recent developments 395
15.1.11.3.1 Deals 395
15.1.11.3.2 Expansions 396
15.1.12 AMECATH 397
15.1.12.1 Business overview 397
15.1.12.2 Products offered 397
15.1.13 MEDICAL COMPONENTS, INC. 400
15.1.13.1 Business overview 400
15.1.13.2 Products offered 400
15.1.13.3 Recent developments 402
15.1.13.3.1 Product launches and approvals 402
15.1.14 HEALTHLINE MEDICAL PRODUCTS 403
15.1.14.1 Business overview 403
15.1.14.2 Products offered 403
15.1.14.3 Recent developments 404
15.1.14.3.1 Deals 404
15.1.15 ACCESS VASCULAR, INC. 405
15.1.15.1 Business overview 405
15.1.15.2 Products offered 405
15.1.15.3 Recent developments 406
15.1.15.3.1 Product launches and approvals 406
15.1.15.3.2 Deals 406
15.1.15.3.3 Other developments 407
15.2 OTHER PLAYERS 408
15.2.1 ARGON MEDICAL DEVICES 408
15.2.2 PAKUMED MEDICAL PRODUCTS GMBH 409
15.2.3 GUANGDONG BAIHE MEDICAL TECHNOLOGY CO., LTD. 410
15.2.4 PFM MEDICAL GMBH 411
15.2.5 MEDI-TECH DEVICES PVT. LTD. 412
15.2.6 KIMAL 413
15.2.7 POLYMED 414
15.2.8 DELTA MED S.P.A. 415
15.2.9 NEWTECH MEDICAL DEVICES PVT. LTD. 416
15.2.10 SHANGHAI PUYI MEDICAL INSTRUMENTS CO., LTD. 417
16 RESEARCH METHODOLOGY 418
16.1 RESEARCH DATA 418
16.1.1 SECONDARY DATA 419
16.1.1.1 Key data from secondary sources 420
16.1.2 PRIMARY DATA 420
16.1.2.1 Key data from primary sources 422
16.1.2.2 Key industry insights 422
16.2 MARKET SIZE ESTIMATION 424
16.3 GROWTH FORECAST 428
16.4 MARKET BREAKDOWN & DATA TRIANGULATION 430
16.5 MARKET RANKING ANALYSIS 431
16.6 STUDY ASSUMPTIONS 431
16.7 RESEARCH LIMITATIONS 431
16.7.1 METHODOLOGY-RELATED LIMITATIONS 431
16.7.2 SCOPE-RELATED LIMITATIONS 432
16.8 RISK ASSESSMENT 432
17 APPENDIX 433
17.1 DISCUSSION GUIDE 433
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 441
17.3 CUSTOMIZATION OPTIONS 443
17.3.1 PRODUCT ANALYSIS 443
17.3.2 GEOGRAPHIC ANALYSIS 443
17.3.3 COMPANY INFORMATION 443
17.4 RELATED REPORTS 443
17.5 AUTHOR DETAILS 444